Kantarjian et al53 assessed the efficacy and security of dasatinib, as when compared with imatinib, for the main-line treatment of CML-CP. Five hundred and nineteen sufferers with newly diagnosed CML-CP were being randomly assigned to get dasatinib at a dose of 100 mg when day by day (259 people) or https://israelrwbgj.amoblog.com/helping-the-others-realize-the-advantages-of-duloxetine-hydrochloride-50668114